Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avacincaptad pegol + aflibercept
- Development stage
- Preclinical
- Lead developer
- Astellas Pharma
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Ophthalmic (intravitreal Injection)
01
Overview
**Avacincaptad pegol + aflibercept** is a combination therapy consisting of avacincaptad pegol, a pegylated RNA aptamer that inhibits complement component 5 (C5), and aflibercept, a recombinant fusion protein acting as a soluble decoy receptor for vascular endothelial growth factors (VEGF-A, VEGF-B) and placental growth factor (PIGF). **Avacincaptad pegol** blocks C5, interrupting the complement cascade, thus preventing inflammatory and cell-destroying events implicated in geographic atrophy secondary to age-related macular degeneration (AMD)[1][3][5]. **Aflibercept** binds and neutralizes VEGF-A, VEGF-B, and PIGF, thus inhibiting angiogenesis and vascular leakage, and is widely used in neovascular (wet) AMD and other retinal vascular diseases[2][4][6]. The combination is being explored for synergistic or complementary effects in AMD and related ocular diseases—targeting both immune-mediated retinal degeneration and pathological angiogenesis.
- Brand names
- Izervay (avacincaptad pegol)Eylea (aflibercept)Zaltrap (parenteral oncology formulation of aflibercept)AhzantivePavbluYesafili
- Other names
- ACP (avacincaptad pegol)VEGF trap (aflibercept)
02
Targets
VEGFB (Vascular endothelial growth factor B)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)C5
Beyond the preview
Go deeper on avacincaptad pegol + aflibercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avacincaptad pegol + aflibercept.